Ned McNamee retweeted
ADC drug development is accelerating. But is biomarker science keeping pace?
Nearly 50% of ADC trials require no biomarker, while most that do still rely on conventional IHC.
In our new @NatRevClinOncol review published just in time pre-#ESMO26, we propose a modular framework to bridge this gap - moving beyond target expression to the multiple biological determinants of ADC efficacy and toxicity.
Proud to lead this international effort with @BarbaraPistill2 @nedmcnamee @rreddel @VivekSubbiah and colleagues.
🔗: nature.com/articles/s41571-0…
Ned McNamee retweeted
The review article @CCR_AACR highlights the limitations of IHC for ADC (e.g. HER2-low) and proposes quantitative proteomics as a key strategy to enhance precision.
aacrjournals.org/clincancerr…
@OncoAlert #ADC
Ned McNamee retweeted
Proud of this work led by @CMRI_AUS PhD student Dr Ned McNamee, tackling one of the central challenges in ADC development: how to identify predictive biomarkers for ADC efficacy.
Quantitative proteomics offers a path forward.
Open access! 🌟
Merry Christmas. 🎁🎄
Now online: Predictive Biomarkers of Antibody-Drug Conjugate Efficacy for Solid Tumors: Current Challenges and the Potential Role of Quantitative Proteomics doi.org/10.1158/1078-0432.CC…
Ned McNamee retweeted
Now online: Predictive Biomarkers of Antibody-Drug Conjugate Efficacy for Solid Tumors: Current Challenges and the Potential Role of Quantitative Proteomics doi.org/10.1158/1078-0432.CC…
Ned McNamee retweeted
Extraordinary work by our ProCan® team for this paper on AI in cancer research out in high-impact oncology journal @CD_AACR, Cancer Discovery, today. Read more here: cmrijeansforgenes.org.au/new…
ALT A person in a white lab coat and blue gloves uses a pipette to dispense liquid into a well plate, positioned inside a laboratory instrument with visible tubes and components.
Ned McNamee retweeted
Combination immunotherapy in pleural mesothelioma may not necessarily be less toxic for certain patients, according to real-world data published recently in @JTOonline. Learn more in #ILCN: ow.ly/EHf250QkIAb @nedmcnamee #LCSM
Ned McNamee retweeted
Mixed growth results from @MovemberAUS, but it is not too late to donate! Thanks to everyone who has contributed to men's health.
movember.com/t/tkcc-mo-bros?…
@docjoshie @AnthonyMJoshua @nedmcnamee #movember #prostatecancer #MerryChristmas #HappyHannukah
Ned McNamee retweeted
Congratulations @nedmcnamee
Australia has one of the highest rates of asbestos-associated diseases. RIOMeso is the 1st detailed report of real-world outcomes for ipilimumab/nivolumab for mesothelioma in Australia, revealing significant toxicity & less prominent survival benefit.bit.ly/46AuJsR #LCSM
Ned McNamee retweeted
Australia has one of the highest rates of asbestos-associated diseases. RIOMeso is the 1st detailed report of real-world outcomes for ipilimumab/nivolumab for mesothelioma in Australia, revealing significant toxicity & less prominent survival benefit.bit.ly/46AuJsR #LCSM
It's almost the end of Movember and we're very close to our goal @kinghorncancer !!
Help us out of you can!
movember.com/t/tkcc-mo-bros?…
@docjoshie @AnthonyMJoshua
Ned McNamee retweeted
The prognosis for brain tumours has always been difficult to define. Today, @HaoWenSim & @nedmcnamee present research at @NeuroOnc on how comprehensive genomic profiling can assist in this astrocytoma prognostication. @Subo81495328 @GarvanInstitute @SVHSydney #OncTwitter
Ned McNamee retweeted
TKCC is whipping up a Movember Team!! Our Mos are in their infancy but hopefully, It will be a fruitful few weeks. @docjoshie @nedmcnamee & @AnthonyMJoshua are leading the charge! If you can, any support would be much appreciated. #Movember @ANZUPtrials
au.movember.com/team/2446720…
Ned McNamee retweeted
Mesothelioma is a rare cancer secondary to asbestos exposure. This week @nedmcnamee, our oncology fellow, presented research on real-world immunotherapy outcomes at @WorldLungCancer. Brilliant job Ned, a rising star in oncology @meg_barnet @chin_venessa @HaoWenSim #OncTwitter
